Free shipping on all orders over $ 500

ATI-2341

Cat. No. M20617
ATI-2341 Structure
Size Price Availability
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization.

Chemical Information
Molecular Weight 2256.82
Formula C104H178N26O25S2
CAS Number 1337878-62-2
Solubility (25°C) DMSO 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Te Jiang, et al. Inflammation. Sigma-1 Receptor Alleviates Airway Inflammation and Airway Remodeling Through AMPK/CXCR4 Signal Pathway

[2] Jess M Planesas, et al. J Mol Graph Model. Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor

[3] Mariusz Z Ratajczak, et al. Expert Opin Biol Ther. The use of chemokine receptor agonists in stem cell mobilization

[4] Jay M Janz, et al. J Am Chem Soc. Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4

[5] Boris Tchernychev, et al. Proc Natl Acad Sci U S A. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells

Related CXCR Products
Vimnerixin

AZD4721 (RIST4721) is a potent and orally active antagonist of the acidic CXC chemokine receptor 2 (CXCR2).AZD4721 has the potential to investigate inflammatory diseases.

ACT-660602

ACT-660602 is an oral chemokine receptor CXCR3 antagonist with an IC50 of 204 nM. It is being developed for use in autoimmune diseases.

ACT-1004-1239

ACT-1004-1239 is a potent, selective, orally administered CXCR7 antagonist with an IC50 value of 3.2 nM.

LIT-927

LIT-927 is a novel neutraligand of CXCL12 with Ki value of 267 nM for inhibition of Texas red-labeled CXCL12 (CXCL12-TR) binding. It shows high selectivity toward CXCL12 vs other chemokines also involved in asthma.

UNBS5162

UNBS5162 is a pan-antagonist of CXCL chemokine expression, with anti-tumor activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: ATI-2341 supplier, CXCR, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.